Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 15

1.

The role of HDL in plaque stabilization and regression: basic mechanisms and clinical implications.

Feig JE, Feig JL, Dangas GD.

Coron Artery Dis. 2016 Nov;27(7):592-603. doi: 10.1097/MCA.0000000000000408.

PMID:
27414247
2.

New Era of Lipid-Lowering Drugs.

Barter PJ, Rye KA.

Pharmacol Rev. 2016 Apr;68(2):458-75. doi: 10.1124/pr.115.012203. Review.

3.

High density lipoproteins: Measurement techniques and potential biomarkers of cardiovascular risk.

Hafiane A, Genest J.

BBA Clin. 2015 Jan 31;3:175-88. doi: 10.1016/j.bbacli.2015.01.005. Review.

4.

Integrative genomics reveals novel molecular pathways and gene networks for coronary artery disease.

Mäkinen VP, Civelek M, Meng Q, Zhang B, Zhu J, Levian C, Huan T, Segrè AV, Ghosh S, Vivar J, Nikpay M, Stewart AF, Nelson CP, Willenborg C, Erdmann J, Blakenberg S, O'Donnell CJ, März W, Laaksonen R, Epstein SE, Kathiresan S, Shah SH, Hazen SL, Reilly MP; Coronary ARtery DIsease Genome-Wide Replication And Meta-Analysis (CARDIoGRAM) Consortium., Lusis AJ, Samani NJ, Schunkert H, Quertermous T, McPherson R, Yang X, Assimes TL.

PLoS Genet. 2014 Jul 17;10(7):e1004502. doi: 10.1371/journal.pgen.1004502.

5.

Regression of atherosclerosis: insights from animal and clinical studies.

Feig JE.

Ann Glob Health. 2014 Jan-Feb;80(1):13-23. doi: 10.1016/j.aogh.2013.12.001. Review.

6.

High-density lipoprotein and atherosclerosis regression: evidence from preclinical and clinical studies.

Feig JE, Hewing B, Smith JD, Hazen SL, Fisher EA.

Circ Res. 2014 Jan 3;114(1):205-13. doi: 10.1161/CIRCRESAHA.114.300760. Review.

7.

Antisense oligonucleotide inhibition of cholesteryl ester transfer protein enhances RCT in hyperlipidemic, CETP transgenic, LDLr-/- mice.

Bell TA 3rd, Graham MJ, Lee RG, Mullick AE, Fu W, Norris D, Crooke RM.

J Lipid Res. 2013 Oct;54(10):2647-57. doi: 10.1194/jlr.M036509.

8.

HDL, Atherosclerosis, and Emerging Therapies.

Hafiane A, Genest J.

Cholesterol. 2013;2013:891403. doi: 10.1155/2013/891403.

9.

Targeting high density lipoproteins in the prevention of cardiovascular disease?

Larach DB, deGoma EM, Rader DJ.

Curr Cardiol Rep. 2012 Dec;14(6):684-91. doi: 10.1007/s11886-012-0317-3. Review.

10.

Cardiovascular disease risk reduction by raising HDL cholesterol--current therapies and future opportunities.

Mahdy Ali K, Wonnerth A, Huber K, Wojta J.

Br J Pharmacol. 2012 Nov;167(6):1177-94. doi: 10.1111/j.1476-5381.2012.02081.x. Review.

11.

Cholesteryl ester transfer protein inhibition as a strategy to reduce cardiovascular risk.

Barter PJ, Rye KA.

J Lipid Res. 2012 Sep;53(9):1755-66. doi: 10.1194/jlr.R024075. Review.

12.

Evacetrapib is a novel, potent, and selective inhibitor of cholesteryl ester transfer protein that elevates HDL cholesterol without inducing aldosterone or increasing blood pressure.

Cao G, Beyer TP, Zhang Y, Schmidt RJ, Chen YQ, Cockerham SL, Zimmerman KM, Karathanasis SK, Cannady EA, Fields T, Mantlo NB.

J Lipid Res. 2011 Dec;52(12):2169-76. doi: 10.1194/jlr.M018069.

13.

Novel HDL-directed pharmacotherapeutic strategies.

Degoma EM, Rader DJ.

Nat Rev Cardiol. 2011 May;8(5):266-77. doi: 10.1038/nrcardio.2010.200. Review.

14.

The ABCG family of membrane-associated transporters: you don't have to be big to be mighty.

Kerr ID, Haider AJ, Gelissen IC.

Br J Pharmacol. 2011 Dec;164(7):1767-79. doi: 10.1111/j.1476-5381.2010.01177.x. Review.

15.

5A apolipoprotein mimetic peptide promotes cholesterol efflux and reduces atherosclerosis in mice.

Amar MJ, D'Souza W, Turner S, Demosky S, Sviridov D, Stonik J, Luchoomun J, Voogt J, Hellerstein M, Sviridov D, Remaley AT.

J Pharmacol Exp Ther. 2010 Aug;334(2):634-41. doi: 10.1124/jpet.110.167890.

Supplemental Content

Support Center